My Cart
0
You have no items in your shopping cart.
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
T126362-10mg | 10mg | 3 | $109.90 | |
T126362-50mg | 50mg | 2 | $385.90 | |
T126362-100mg | 100mg | 3 | $701.90 |
Potent, selective PPAR-γ receptor agonist
Synonyms | CS045 | CS-045 | HSCI1_000037 | DTXSID8023719 | Q7844989 | Rezulin (TN) | SR-05000000454-5 | 5-[(4-{[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methyl]oxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione | AB00643330-02 | Troglitazone (JAN/USAN/I |
---|---|
Specifications & Purity | Moligand™, ≥96% |
Biochemical and Physiological Mechanisms | Troglitazone has been shown to be a potent antiproliferative and apoptosis inducer. This compound has displayed a capacity to inhibit growth of HCC cells via G1 phase cell cycle arrest through hypophosphorylation of Rb (retinoblastoma) protein and an incr |
Storage Temp | Store at -20°C,Argon charged |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | AGONIST, CHANNEL BLOCKER |
Mechanism of action | Agonist of Peroxisome proliferator-activated receptor-γ;Channel blocker of TRPM3 |
Note | Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details. |
Product Description | Troglitazone(CS-045), PPARγ agonist, is an anti-diabetic thiazolidinedione (TZD) with anti-inflammatory and anti-tumor activity. |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Pubchem Sid | 504750916 |
---|---|
Pubchem Sid Url | https://pubchem.ncbi.nlm.nih.gov/substance/504750916 |
IUPAC Name | 5-[[4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione |
INCHI | InChI=1S/C24H27NO5S/c1-13-14(2)21-18(15(3)20(13)26)9-10-24(4,30-21)12-29-17-7-5-16(6-8-17)11-19-22(27)25-23(28)31-19/h5-8,19,26H,9-12H2,1-4H3,(H,25,27,28) |
InChi Key | GXPHKUHSUJUWKP-UHFFFAOYSA-N |
Canonical SMILES | CC1=C(C2=C(CCC(O2)(C)COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4)C(=C1O)C)C |
Isomeric SMILES | CC1=C(C2=C(CCC(O2)(C)COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4)C(=C1O)C)C |
PubChem CID | 5591 |
Molecular Weight | 441.54 |
Find and download the COA for your product by matching the lot number on the packaging.
11 results found
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
Certificate of Analysis | Feb 19, 2025 | T126362 | |
Certificate of Analysis | Feb 19, 2025 | T126362 | |
Certificate of Analysis | Feb 19, 2025 | T126362 | |
Certificate of Analysis | Aug 22, 2024 | T126362 | |
Certificate of Analysis | Jul 08, 2024 | T126362 | |
Certificate of Analysis | Jul 08, 2024 | T126362 | |
Certificate of Analysis | Jul 08, 2024 | T126362 | |
Certificate of Analysis | Feb 07, 2023 | T126362 | |
Certificate of Analysis | Jun 01, 2022 | T126362 | |
Certificate of Analysis | Jun 01, 2022 | T126362 |
Solubility | Soluble in ethanol (>25 mg/ml) at 50 °C, DMSO (>25 mg/ml), DMF (30 mg/ml), DMSO:PBS (1:6, pH 7.2) (0.1 mg/ml), and water (0.1 mg/ml) at 25 °C. |
---|---|
Sensitivity | Air Sensitive,Heat Sensitive |
Melt Point(°C) | 177 °C |
Molecular Weight | 441.500 g/mol |
XLogP3 | 5.100 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 5 |
Exact Mass | 441.161 Da |
Monoisotopic Mass | 441.161 Da |
Topological Polar Surface Area | 110.000 Ų |
Heavy Atom Count | 31 |
Formal Charge | 0 |
Complexity | 681.000 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 2 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
The total count of all stereochemical bonds | 0 |
Covalently-Bonded Unit Count | 1 |
Merck Index | 9769 |
---|
1. Shuai Liu, Keming Zheng, Yilin Jiang, Susu Gai, Bohan Li, Dehai Li, Shuang Yang, Zhihua Lv. (2023) Biotransformation of Penindolone, an Influenza A Virus Inhibitor. MOLECULES, 28 (3): (1479). [PMID:36771146] [10.3390/molecules28031479] |
2. Xie Qiu-shi, Zhang Jia-xin, Liu Ming, Liu Pei-hua, Wang Zhong-jian, Zhu Liang, Jiang Ling, Jin Meng-meng, Liu Xiao-nan, Liu Li, Liu Xiao-dong. (2020) Short-chain fatty acids exert opposite effects on the expression and function of p-glycoprotein and breast cancer resistance protein in rat intestine. ACTA PHARMACOLOGICA SINICA, 42 (3): (470-481). [PMID:32555444] [10.1038/s41401-020-0402-x] |
1. Pinkosky SL et al.. (2016) Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis.. Nat Commun, 7 (13457). [PMID:27892461] |
2. Zhu HY et al.. (2016) Peroxisome proliferator-activated receptor-? agonist inhibits collagen synthesis in human keloid fibroblasts by suppression of early growth response-1 expression through upregulation of miR-543 expression.. Am J Cancer Res, 6 (6): (1358-70). [PMID:27429849] |
3. Zhu HY et al.. (2016) Peroxisome proliferator-activated receptor-? agonist troglitazone suppresses transforming growth factor-ß1 signalling through miR-92b upregulation-inhibited Axl expression in human keloid fibroblasts in vitro.. Am J Transl Res, 8 (8): (3460-70). [PMID:27648136] |
4. Shuai Liu, Keming Zheng, Yilin Jiang, Susu Gai, Bohan Li, Dehai Li, Shuang Yang, Zhihua Lv. (2023) Biotransformation of Penindolone, an Influenza A Virus Inhibitor. MOLECULES, 28 (3): (1479). [PMID:36771146] [10.3390/molecules28031479] |
5. Xie Qiu-shi, Zhang Jia-xin, Liu Ming, Liu Pei-hua, Wang Zhong-jian, Zhu Liang, Jiang Ling, Jin Meng-meng, Liu Xiao-nan, Liu Li, Liu Xiao-dong. (2020) Short-chain fatty acids exert opposite effects on the expression and function of p-glycoprotein and breast cancer resistance protein in rat intestine. ACTA PHARMACOLOGICA SINICA, 42 (3): (470-481). [PMID:32555444] [10.1038/s41401-020-0402-x] |